Design and optimization of selective azaindole amide M1 positive allosteric modulators

https://doi.org/10.1016/j.bmcl.2015.11.053Get rights and content

Abstract

Selective activation of the M1 receptor via a positive allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments associated with schizophrenia and Alzheimer’s disease. A novel series of azaindole amides and their key pharmacophore elements are described. The nitrogen of the azaindole core is a key design element as it forms an intramolecular hydrogen bond with the amide N–H thus reinforcing the bioactive conformation predicted by published SAR and our homology model. Representative compound 25 is a potent and selective M1 PAM that has well aligned physicochemical properties, adequate brain penetration and pharmacokinetic (PK) properties, and is active in vivo. These favorable properties indicate that this series possesses suitable qualities for further development and studies.

Section snippets

Acknowledgements

We would like to acknowledge Anabella Villalobos, and Bruce Rogers for helpful discussions and Tim McNally, Sarah Neal, Katherine Brighty, Laurence Philippe, and HD Biosciences for technical assistance.

References and notes (25)

  • (a)Sakamoto, H.; Sugimoto, T. WO 13129622 20130906,...Z.Q. Yang et al.

    ACS Med. Chem. Lett.

    (2014)
  • T.T. Wager et al.

    ACS Chem. Neurosci.

    (2010)
  • M.L. Lewis et al.

    J. Comput. Aided Mol. Des.

    (2009)
  • P.S. Shirude et al.

    J. Med. Chem.

    (2013)
    P.S. Shirude et al.

    J. Med. Chem.

    (2014)
  • R.M. Eglen

    Handb. Exp. Pharmacol.

    (2012)
  • D.J. Foster et al.

    Neuropsychiatr. Dis. Treat.

    (2014)
  • N.C. Bodick et al.

    Arch. Neurol.

    (1997)
    A. Shekhar et al.

    Am. J. Psychiatry

    (2008)
  • J.K. Shirey et al.

    J. Neurosci.

    (2009)
    C.C. Felder et al.

    J. Med. Chem.

    (2000)
    A.I. Levey

    Proc. Natl. Acad. Sci. U.S.A.

    (1996)
  • A.D. Korczyn

    Expert Opin. Investig. Drugs

    (2000)
  • A.C. Kruse et al.

    Nature

    (2013)
  • L. Ma et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2009)
  • A. Abdul-Ridha et al.

    J. Biol. Chem.

    (2014)
  • Cited by (33)

    • Pyrido triazin-nucleus synthesis and theoretical studies: 2,3,6-trioxo-8-aryl-1,3,4,6-tetrahydro-]2H[pyrido]1,2-b] [1,2,4[triazin-7,9-dicarbonitryl derivatives

      2021, Journal of Molecular Structure
      Citation Excerpt :

      For example, the IMHBs can stabilize the bioactive compound of a certain ligand. This decreases the translational and conformational entropy upon binding and lead to stronger connection [28–31] Several theoretical approaches can be applied to study HBs, for example atoms in molecules (AIM) methodology [32,33]. The AIM theory of Bader [34] was applied to analyze the topological properties of the bond critical point (BCP) of the hydrogen bond.

    • Allosteric modulators targeting GPCRs

      2019, GPCRs: Structure, Function, and Drug Discovery
    • The discovery of VU0486846: steep SAR from a series of M<inf>1</inf> PAMs based on a novel benzomorpholine core

      2018, Bioorganic and Medicinal Chemistry Letters
      Citation Excerpt :

      M1 (muscarinic acetylcholine receptor subtype 1) positive allosteric modulators (PAMs) represent an exciting therapeutic strategy to treat multiple domains of cognitive dysfunction in CNS disorders such as schizophrenia and Alzheimer’s disease.1–5 However, the great potential of this target has been hindered, originally by nonselective orthosteric ligands (1),6 and then by potent ago-PAMs 2–5 (in cell lines (M1 PAM EC50s < 100 nM) and M1 agomist potency <1 μM) and native tissues) that proved to be cognitive disrupting and proconvulsive due to over stimulation of the M1 receptor (Fig. 1).7–12 Recently, we disclosed the first M1 PAM free from adverse events, VU6004256 (6),13 and with robust efficacy in NMDA receptor 1 (NR1) knock-down mice.14

    View all citing articles on Scopus
    View full text